Deva Holding stock fell 1.55 percent on October 7

Published on 10/08/2026 at 06:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Deva Holding stock was last at TRY 86.00 on October 7, 2026, with a 52-week range of TRY 57.50 to TRY 109.30. Six-month 2026 sales reached TRY 12.3 billion and net profit was TRY 516.8 million.

Deva Holding, TRADEVAW91E2, Illustration mit AI erstellt.

Deva Holding stock (ISIN TRADEVAW91E2) fell 1.55 percent on October 7, 2026, while 206,690 shares changed hands on Borsa Istanbul. The move gives investors a fresh market reference alongside the companys latest first-half figures.

First-half sales reach TRY 12.3 billion

According to FVT, Deva Holding reported TRY 12.3 billion in net sales and TRY 516.8 million in net profit for the first six months of 2026. The same period included TRY 2.2 billion in EBITDA, giving the earnings picture a profitability measure beyond revenue alone.

Yatirimci.ai lists the latest 2026/6 period with TRY 6.4 billion in quarterly sales, TRY 1.5 billion in EBITDA and TRY 607.7 million in net profit. The quarterly and first-half figures use different reporting bases, so they describe separate points in the companys 2026 performance rather than a direct like-for-like comparison.

Stock remains below its yearly high

Deva Holding was last at TRY 86.00 on Borsa Istanbul on October 7, 2026 at 6:09 p.m. TRT. That level stood 21.3 percent below the 52-week high of TRY 109.30 and TRY 28.50 above the 52-week low of TRY 57.50.

The companys market capitalization was TRY 17.2 billion on the same date. Makkler identifies Deva Holding A.S. as a BIST-listed health technology company under ticker DEVA and assigns ISIN TRADEVAW91E2.

Pharmaceutical portfolio spans 15 areas

DEVA Holding says it has more than 67 years of operating experience, supplies healthcare solutions to more than 80 countries and works across 15 therapeutic areas. Its activities include human pharmaceuticals, active pharmaceutical ingredients and veterinary pharmaceuticals.

For investors, the key contrast is clear: the stock is below its yearly peak while the latest reported periods contain multi-billion-lira sales, EBITDA and profit figures. The October 7 price change and the first-half results therefore provide separate measures of market valuation and operating performance.